Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Supernus Pharmaceuticals Inc shares valued at $387,768 were sold by NEWHALL CHARLES W III on Nov 11 ’24. At $36.24 per share, NEWHALL CHARLES W III sold 10,700 shares. The insider’s holdings dropped to 130,275 shares worth approximately $4.82 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Hudson Frederick M. sold 8,722 shares, netting a total of over 316,434 in proceeds. Following the sale of shares at $36.28 each, the insider now holds 28,395 shares.
Before that, GEMAYEL GEORGES had sold 10,787 shares from its account. In a trade valued at $391,568, the Director traded Supernus Pharmaceuticals Inc shares for $36.30 each. Upon closing the transaction, the insider’s holdings decreased to 10,787 shares, worth approximately $0.49 million.
As published in a research note from Piper Sandler on September 11, 2024, Supernus Pharmaceuticals Inc [SUPN] has been rated down from an Overweight to a Neutral and the price target has been revised to $36 from $41. Earlier on April 13, 2021, Jefferies upgraded its rating. Their new recommendation was “a Buy” for SUPN stock which previously was a “a Hold”.
Analyzing SUPN Stock Performance
During the last five days, there has been a surge of approximately 2.41%. Over the course of the year, Supernus Pharmaceuticals Inc shares have jumped approximately 27.82%. Shares of the company reached a 52-week high of $39.37 on 11/05/24 and a 52-week low of $25.53 on 06/14/24. A 50-day SMA is recorded $34.00, while a 200-day SMA reached $31.26. Nevertheless, trading volume fell to 0.5 million shares from 0.28 million shares the previous day.
Support And Resistance Levels for Supernus Pharmaceuticals Inc (SUPN)
According to the 24-hour chart, there is a support level at 36.27, which, if violated, would cause prices to drop to 35.55. In the upper region, resistance lies at 37.47. The next price resistance is at 37.95. RSI (Relative Strength Index) is 61.27 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.07, which suggests the price will decrease in the coming days. Percent R is at 38.44%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
